4Vote!
TaylorTree (Free subscription) | 08/23/2009
Test Stocks Symbol Name Status FLWS 1-800 FLOWERS COM this is just a test YHOO YAHOO CORP no status TDSC 3d Systems Corp MMM 3m Co PAR 3par Inc NDN 99 Cents Only Stores AAON Aaon Inc AIR Aar Corp AAN Aarons Inc ABAX Abaxis Inc ABT Abbott Laboratories ANF Abercrombie & Fitch ABBC Abington Bancorp Inc ABMD Abiomed Inc ABM Abm Industries Inc ABVT Abovenet Inc ABII Abraxis Bioscience Inc ACTG Acacia...
Explore : 3M,
99 Cents Only Stores,
Abbott Laboratories,
Abercrombie and Fitch,
Accenture Limited,
ACCO Brands Corporation,
Accounting and Auditing,
Acxiom Corp.,
Adaptec,
Apparel,
Business,
Conglomerates,
Discount Stores,
Drug Manufacturers,
Fashion Industry,
Health Industries,
IT Services,
Office Supplies and Equipment,
Retailers,
Search Engines,
Technology,
Telecommunication
3Vote!
Medical News Today (Free subscription) | 05/29/2009
Abraxis BioScience Inc. (NASDAQ:ABII) announced that final results from an open-label Phase II study evaluating three dose levels of the company's chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) compared to the highest standard dose of Taxotere (docetaxel) Injection Concentrate, in the first-line treatment of...
1Vote!
Business Wire (Free subscription) | 05/28/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience Inc. (NASDAQ:ABII) announced today that final results from an open-label Phase II study evaluating three dose levels of the company’s chemotherapy agent
4Vote!
Business Wire (Free subscription) | 05/12/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable
4Vote!
Business Wire (Free subscription) | 05/07/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2009.
1Vote!
DealBook (Free subscription) | 05/06/2009
It's safety first at Abraxis BioScience , which spent $1.3 million in 2008 to provide its chief executive with security-related services, according to its recent proxy statement.
4Vote!
Business Wire (Free subscription) | 05/05/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced today that Lonnie Moulder, President and Chief Executive Officer, will present a company
1Vote!
Business Wire (Free subscription) | 04/30/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that Leon (Lonnie) O. Moulder, Jr., has been appointed Vice Chairman, President and Chief
4Vote!
Business Wire (Free subscription) | 04/29/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced it will release its 2009 first quarter financial results before the market opens on
3Vote!
Medical News Today (Free subscription) | 04/22/2009
Abraxis BioScience Inc. (NASDAQ: ABII) announced that multiple studies showcasing its proprietary tumor targeting technology, known as the nab® (nanoparticle albumin-bound) technology platform, and secreted protein acidic and rich in cysteine (SPARC) biomarker will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Denver, April 18-22, 2009.
5Vote!
Newswise (Free subscription) | 04/21/2009
Abraxis BioScience presents preclinical and clinical results from 10 studies evaluating chemotherapeutic agent ABRAXANE (R), SPARC Biomarker and Other Nab(R) Pipeline Therapies at AACR Annual Meeting.
4Vote!
Business Wire (Free subscription) | 04/20/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today announced that its board of directors authorized a program to repurchase up to $100 million of the
4Vote!
Business Wire (Free subscription) | 04/08/2009
PORTLAND, Ore.--(BUSINESS WIRE)--Dossia today announced Abraxis BioScience Inc. as the newest member of the Dossia Founders Group, joining eight major U.S. employers dedicated to empowering employees to make smarter,
4Vote!
Business Wire (Free subscription) | 03/03/2009
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported financial results for the fourth quarter and full year ended December 31, 2008.
Videos